Aruba Aloë Formula F-BC-096 in the Treatment of Split Thickness Donor Sites After Wound Closure
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00389753|
Recruitment Status : Suspended (study never started)
First Posted : October 19, 2006
Last Update Posted : September 29, 2010
|Condition or disease||Intervention/treatment||Phase|
|Hydration of Scars||Drug: Application of Aruba Aloë formula F-BC-096 or control||Not Applicable|
Patients with two equal donor sites will be selected for inclusion. After wound healing one donor site will be treated with Aruba Aloë Formula F-BC-096 while a control product will be applied to the second site.
If pressure garments are applied they must be equal for both donor sites. During follow-ups objective methods will be used to evaluate elasticity and colour of the scar.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||A Prospective, Randomized, Double Blinded Controlled Clinical Trial of the Aruba Aloë Formula F-BC-096 in the Treatment of Split Thickness Donor Sites After Wound Closure|
- Scar assessment after 1 month
- Scar assessment 3, 6 and 12 months after wound closure
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00389753
|University Hospital Ghent|
|Ghent, Belgium, 9000|
|Principal Investigator:||Stan Monstrey, MD, PhD||University Hospital, Ghent|